Business
Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
First and only medication authorized in Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome. Approval supported by more than
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nFirst and only medication authorized in Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome.\n\n\n\nApproval supported by more than six years of LIVMARLI data demonstrating improvements in pruritus and serum bile acids.\n\n\n\nData from LIVMARLI clinical trials published in The Lancet and Hepatology\n\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725391772/en/LIVMARLI (maralixibat oral solution) (Graphic: Business Wire)\nALGS is a rare genetic disorder caused by abnormalities in bile ducts that can lead to progressive liver disease. Malformed or reduced bile ducts cause cholestasis, the accumulation of bile acids in the liver, which leads to inflammation and liver injury, and prevents the liver from working properly. Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.\n\n\n“Today’s approval in Canada furthers our commitment to ensuring patients globally have a meaningful and effective treatment option for the unrelenting burden of cholestatic pruritus impacting patients and their families living with ALGS,” said Chris Peetz, president and chief executive officer at Mirum. “We are grateful to the patients, families, clinicians and ALGS community who made this approval possible.”\n\n\n“There have been meaningful advances in the treatment of Alagille syndrome with the approval of LIVMARLI and I am pleased that it is now available in Canada where I have seen, firsthand, the critical need for an approved therapy to address the itch caused by cholestasis. The years of data collected have shown that LIVMARLI can provide tremendous benefit, potentially giving many patients the opportunity to live transplant-free,” said Dr. Binita Kamath, Hospital for Sick Children (SickKids), Toronto, Canada. “The statistical robustness of results seen in the LIVMARLI studies give confidence that this treatment has the potential to have meaningful outcomes for patients with debilitating pruritus.”\n\n\n“We are thrille...